
Formulation Recommendation



100 mg Taste-Masked IBU Orally Dispersible Powder (TM IBU ODP)

Composition	% (By Weight)	mg / Tablet
● 1 Actimask® IBU º	13.59	108.70
2 Pharmasperse® 416	82.36	658.90
3 Grape Flavor	2.00	16.00
4 Sucralose	1.00	8.00
5 Tartaric Acid	1.00	8.00
6 FD&C Purple	0.05	0.40
Final Tablet Weight		800.00



Method

- 1. Weigh the components individually and screen using a #20-mesh sieve.
- 2. Mix all ingredients in an 8-qt V-blender at 25rpm for 15 minutes.
- 3. Weigh 800 mg aliquots and seal within a sachet.

Your Partner for Formulating Success

Americas SPI Pharma, Inc. Rockwood Office Park 503 Carr Rd., Suite 210 Wilmington, DE 19809

T 302 576 8600 800 789 9755 Ext. 8600 F 302 576 8567 Europe/Middle East/ Africa SPI Pharma SAS Chemin du Vallon du Maire 13240 Septemes-Les Vallons France

T 33 4 9196 3600 F 33 4 9196 3633 Asia/Pacific SPI Pharma, Inc – India Branch 21 B, Veerasandra Industrial Area Hosur Road, Bangalore – 560100 Karnataka, India

T 91 80 3027 0005 F 91 80 3027 0050 Australia Distribution Company Anzchem 1 Braidwood Street Enfield NSW 2136 Australia

T 61 2 9475 2200 F 61 2 9475 2211 www.spipharma.com



All trademarks are the property of SPI Pharma. Copyright SPI Pharma 2013. The information contained in this document is proprietary to SPI Pharma and may not be used or disseminated inappropriately. The information and recommendations contained herein are to the best of SPI Pharma, Inc.'s knowledge reliable and accurate. Any recommendations are made without warranty, either implied or expressed, due to the variations in equipment, conditions, and methods which may be used in commercially processing the products. No warranties of any kind are made, express or implied, including those of merchantability and fitness for particular purpose, other than the products conform to current standard specifications. SPI Pharma, Inc. makes no warranty that the use of the products or formulations provided by SPI Pharma, Inc. will not infringe any trademark, trade name, copyright, patent or other rights held by any third party when used in customer's application. SPI Pharma, Inc. shall not be liable for loss of profit or for incidental, special or consequential loss or damage.